Literature DB >> 19584402

Identification of cancer stem cells in a Tax-transgenic (Tax-Tg) mouse model of adult T-cell leukemia/lymphoma.

Jumpei Yamazaki1, Takuo Mizukami, Kazuya Takizawa, Madoka Kuramitsu, Haruka Momose, Atsuko Masumi, Yasushi Ami, Hideki Hasegawa, William W Hall, Hajime Tsujimoto, Isao Hamaguchi, Kazunari Yamaguchi.   

Abstract

Adult T-cell leukemia/lymphoma (ATL) is a malignant lymphoproliferative disorder caused by HTLV-I infection. In ATL, chemotherapeutic responses are generally poor, which has suggested the existence of chemotherapy-resistant cancer stem cells (CSCs). To identify CSC candidates in ATL, we have focused on a Tax transgenic mouse (Tax-Tg) model, which reproduces ATL-like disease both in Tax-Tg animals and also after transfer of Tax-Tg splenic lymphomatous cells (SLCs) to nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice. Using a limiting dilution transplantation, it was estimated that one CSC existed per 10(4) SLCs (0.01%). In agreement with this, we have successfully identified candidate CSCs in a side population (0.06%), which overlapped with a minor population of CD38(-)/CD71(-)/CD117(+) cells (0.03%). Whereas lymphoma did not develop after transplantation of 10(2) SLCs, 10(2) CSCs could consistently regenerate the original lymphoma. In addition, lymphoma and CSCs could also be demonstrated in the bone marrow and CD117(+) CSCs were observed in both osteoblastic and vascular niches. In the CSCs, Tax, Notch1, and Bmi1 expression was down-regulated, suggesting that the CSCs were derived from Pro-T cells or early hematopoietic progenitor cells. Taken together, our data demonstrate that CSCs certainly exist and have the potential to regenerate lymphoma in our mouse model.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19584402     DOI: 10.1182/blood-2008-08-174425

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

Review 1.  Molecular mechanisms of HTLV-1 infection and pathogenesis.

Authors:  Junichiro Yasunaga; Masao Matsuoka
Journal:  Int J Hematol       Date:  2011-09-28       Impact factor: 2.490

2.  Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.

Authors:  A Lonetti; I L Antunes; F Chiarini; E Orsini; F Buontempo; F Ricci; P L Tazzari; P Pagliaro; F Melchionda; A Pession; A Bertaina; F Locatelli; J A McCubrey; J T Barata; A M Martelli
Journal:  Leukemia       Date:  2013-11-06       Impact factor: 11.528

3.  Adult T-cell leukemia/lymphoma development in HTLV-1-infected humanized SCID mice.

Authors:  Prabal Banerjee; Adam Tripp; Michael D Lairmore; Lindsey Crawford; Michelle Sieburg; Juan Carlos Ramos; William Harrington; Mark A Beilke; Gerold Feuer
Journal:  Blood       Date:  2010-02-01       Impact factor: 22.113

Review 4.  Hematopoietic stem cells and retroviral infection.

Authors:  Prabal Banerjee; Lindsey Crawford; Elizabeth Samuelson; Gerold Feuer
Journal:  Retrovirology       Date:  2010-02-04       Impact factor: 4.602

5.  Animals Models of Human T Cell Leukemia Virus Type I Leukemogenesis.

Authors:  Stefan Niewiesk
Journal:  ILAR J       Date:  2016

Review 6.  Targeting HTLV-1 activation of NFκB in mouse models and ATLL patients.

Authors:  Daniel A Rauch; Lee Ratner
Journal:  Viruses       Date:  2011-06-21       Impact factor: 5.048

7.  Molecular hallmarks of adult T cell leukemia.

Authors:  Makoto Yamagishi; Toshiki Watanabe
Journal:  Front Microbiol       Date:  2012-09-17       Impact factor: 5.640

8.  HTLV-I tax increases genetic instability by inducing DNA double strand breaks during DNA replication and switching repair to NHEJ.

Authors:  Hicham H Baydoun; Xue Tao Bai; Shary Shelton; Christophe Nicot
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

9.  Animal models on HTLV-1 and related viruses: what did we learn?

Authors:  Hiba El Hajj; Rihab Nasr; Youmna Kfoury; Zeina Dassouki; Roudaina Nasser; Ghada Kchour; Olivier Hermine; Hugues de Thé; Ali Bazarbachi
Journal:  Front Microbiol       Date:  2012-09-21       Impact factor: 5.640

Review 10.  Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.

Authors:  Alberto M Martelli; Francesca Chiarini; Camilla Evangelisti; Alessandra Cappellini; Francesca Buontempo; Daniela Bressanin; Milena Fini; James A McCubrey
Journal:  Oncotarget       Date:  2012-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.